SynuClean-D is primarily researched for its potential in combating neurodegenerative diseases, particularly those involving protein aggregation, such as Alzheimer's and Parkinson's. It has shown promise in inhibiting the aggregation of amyloid-beta peptides and alpha-synuclein, which are key contributors to the progression of these diseases. By preventing the formation of toxic protein aggregates, it may help slow down or mitigate neuronal damage. Additionally, its antioxidant properties contribute to reducing oxidative stress, a common factor in neurodegeneration. While still in the experimental stages, SynuClean-D represents a potential therapeutic candidate for targeting the underlying mechanisms of these debilitating conditions.